• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc. (Amendment)

    6/12/23 5:02:48 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email
    SC 13D/A 1 d701368dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Option Care Health, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    68404L201

    (CUSIP Number)

    Danielle C. Gray

    Executive Vice President, Global Chief Legal Officer

    Walgreens Boots Alliance, Inc.

    108 Wilmot Road

    Deerfield, Illinois 60015

    (847) 315-2500

    with a copy to:

    Lillian Tsu

    Cleary Gottlieb Steen & Hamilton LLP

    One Liberty Plaza

    New York, NY 10006

    (212) 225-2000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 8, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 68404L201       SCHEDULE 13D       Page 2 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Walgreens Boots Alliance, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO (See item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.0% (1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO, HC

     

    (1)

    This calculation is based on 179,764,281 shares of Common Stock outstanding as of May 2, 2023 (as represented by the Issuer in its most recently filed 10-Q on May 4, 2023).


    CUSIP NO. 68404L201       SCHEDULE 13D       Page 3 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      HC Group Holdings I, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

          (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO (See item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.0% (1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    (1)

    This calculation is based on 179,764,281 shares of Common Stock outstanding as of May 2, 2023 (as represented by the Issuer in its most recently filed 10-Q on May 4, 2023).


    CUSIP NO. 68404L201       SCHEDULE 13D       Page 4 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      OCH US Holding LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO (See item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.0% (1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO, HC

     

    (1)

    This calculation is based on 179,764,281 shares of Common Stock outstanding as of May 2, 2023 (as represented by the Issuer in its most recently filed 10-Q on May 4, 2023).


    CUSIP NO. 68404L201       SCHEDULE 13D       Page 5 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      WBA US 1 Co.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO (See item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.0% (1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO, HC

     

    (1)

    This calculation is based on 179,764,281 shares of Common Stock outstanding as of May 2, 2023 (as represented by the Issuer in its most recently filed 10-Q on May 4, 2023).


    CUSIP NO. 68404L201       SCHEDULE 13D       Page 6 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      WBA Investments, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO (See item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.0% (1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO, HC

     

    (1)

    This calculation is based on 179,764,281 shares of Common Stock outstanding as of May 2, 2023 (as represented by the Issuer in its most recently filed 10-Q on May 4, 2023).


    CUSIP NO. 68404L201       SCHEDULE 13D       Page 7 of 9 Pages

     

    Explanatory Note

    This Amendment No. 3 to Schedule 13D (this “Amendment No. 3”) amends and supplements the Schedule 13D (the “Schedule 13D”) relating to the common stock, $0.0001 par value per share (“Common Stock”), of Option Care Health, Inc., a Delaware corporation (the “Issuer”), originally filed with the Securities and Exchange Commission (the “SEC”) on December 20, 2021, as amended by Amendment No. 1 thereto filed on August 18, 2022 and Amendment No. 2 thereto filed on March 3, 2023.

    Terms used but not defined in this Amendment No. 3 have the respective meanings given to such terms in the original Schedule 13D, as previously amended.

    Because the Reporting Persons no longer beneficially own greater than 5% of the Issuer’s outstanding securities, this Amendment No. 3 is the final amendment to the Schedule 13D and is an exit filing for the Reporting Persons.

    Item 4. Purpose of Transaction.

    Item 4 is amended and supplemented as follows by adding the following:

    June 2023 Equity Offering

    On June 8, 2023, HC I sold 10,771,926 shares of the of common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”) in an unregistered block trade pursuant to Rule 144 under the Securities Act of 1933, as amended (the “June 2023 Sale”), representing approximately 5.99% of the outstanding Common Stock as of May 2, 2023 (as represented by the Issuer in its most recently filed 10-Q on May 4, 2023). As a result of the June 2023 Sale, HC I’s ownership of the Issuer declined from approximately 5.99% of the Common Stock to 0.0% of the Common Stock.

    Upon closing of the June 2023 Sale, HC I will cease to beneficially own (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) any shares of Common Stock.

    Item 5. Interest in Securities of the Issuer.

    Item 5 is amended and supplemented as follows:

    (a, b)


    After giving effect to the transaction described in Item 4 hereof, none of the Reporting Persons has voting or dispositive power with respect to any shares of the Issuer’s Common Stock and therefore have beneficial ownership of approximately 0% of the total number of shares of Common Stock outstanding.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the shares of the Issuer’s Common Stock referred to herein for the purposes of Section 13(d) of the Act, or for any other purpose, and such beneficial ownership is expressly disclaimed by each Reporting Person other than HC I.

    Each Reporting Person expressly disclaims any assertion or presumption that it and the other persons on whose behalf this Schedule 13D is filed constitute a “group” for the purposes of Sections 13(d) of the Act and the rules thereunder. The filing of this Schedule 13D should not be construed to be an admission that any member of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) of the Act.

    (c)

    The information set forth in Item 4 of this Schedule 13D is incorporated by reference in its entirety into this Item 5(c). Except for the information disclosed in Item 4 of this Schedule 13D, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock in the past 60 days.

    (d)

    None of the Reporting Persons, and to the best knowledge of the Reporting Persons, no other person, is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of the Issuer’s Common Stock reported herein.

    (e)

    As June 8, 2023, the Reporting Persons ceased to be the beneficial owner of more than five percent of the issued and outstanding shares of Common Stock of the Issuer. The filing of this Amendment No. 3 constitutes an exit filing for the Reporting Persons.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Item 6 is amended by adding the following:

    The information set forth in Item 4 of this Amendment No. 3 is incorporated by reference in its entirety into this Item 6.

    Item 7. Materials to be Filed as Exhibits.

     

    Exhibit 1    Joint Filing Agreement, by and among the Reporting Persons, dated as of December  20, 2021(incorporated by reference to Exhibit 1 of the Schedule 13D filed by the Reporting Persons on December 20, 2021).
    Exhibit 2    Registration Rights Agreement, by and among the Issuer and HC I (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the SEC on August 7, 2019).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

    Dated: June 12, 2023

     

    WALGREENS BOOTS ALLIANCE, INC.
    By:   /s/ Joseph B. Amsbary, Jr.
    Name: Joseph B. Amsbary, Jr.
    Title: Senior Vice President and Corporate Secretary
    HC GROUP HOLDINGS I, LLC
    By:   /s/ Joseph B. Amsbary, Jr.
    Name: Joseph B. Amsbary, Jr.
    Title: Senior Vice President and Secretary
    OCH US HOLDING LLC
    By:   /s/ Joseph B. Amsbary, Jr.
    Name: Joseph B. Amsbary, Jr.
    Title: Senior Vice President and Secretary
    WBA US 1 CO.
    By:   /s/ Joseph B. Amsbary, Jr.
    Name: Joseph B. Amsbary, Jr.
    Title: Senior Vice President and Secretary
    WBA INVESTMENTS, INC.
    By:   /s/ Joseph B. Amsbary, Jr.
    Name: Joseph B. Amsbary, Jr.
    Title: Senior Vice President and Secretary
    Get the next $WBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      10/18/24 12:45:41 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

      SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

      8/20/24 4:05:58 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      2/13/24 5:17:30 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Financials

    Live finance-specific insights

    See more
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Suspends Quarterly Dividend as Company Continues Disciplined Execution Against Strategic Priorities

      Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,

      1/30/25 4:55:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens Debuts PharmStart to Strengthen the Tech to Pharmacist Pipeline

      First-of-its-kind program aims to reduce pre-requisite costs, which remain common barriers for pharmacy technicians looking to pursue a PharmD degree. Walgreens, the nation's largest independent community pharmacy provider, has teamed up with Guild, the leading talent development company, to launch PharmStart, a first-of-its-kind, fully funded online education program designed to help eligible team members meet the prerequisite requirements for pharmacy school. The program aims to eliminate barriers to pursuing a PharmD degree, tapping into a new pool of talent while also addressing critical challenges in the pharmacist talent pipeline. This press release features multimedia. View the full

      4/23/25 6:30:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025

      Walgreens is calling on the public to help in the fight against prescription drug abuse by participating in National Prescription Drug Take Back Day on Saturday, April 26th, 2025. Drug take-back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,500 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421063789/en/Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025 This public

      4/21/25 12:13:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

      2/28/25 7:36:45 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

      Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

      2/26/24 8:28:07 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance downgraded by HSBC Securities

      HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

      2/20/24 10:23:30 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    See more

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $WBA
    SEC Filings

    See more
    • Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

      Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

      10/7/24 8:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

      Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

      8/16/24 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

      NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc

      7/12/24 8:00:00 PM ET
      $NDAQ
      $SMCI
      $WBA
      Investment Bankers/Brokers/Service
      Finance
      Computer Manufacturing
      Technology
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/2/24 6:40:23 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Lederer John Anthony

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/18/25 5:58:32 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Huffines Robert Luther

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/18/25 5:56:27 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      5/9/25 4:05:42 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      5/8/25 5:20:44 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SCHEDULE 13D/A filed by Walgreens Boots Alliance Inc.

      SCHEDULE 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      4/29/25 9:57:03 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples